Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 253

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 253
---
838

    13,685

    Current portion of operating lease liabilities

    10,239

    9,384

    Current portion of deferred revenue

    55,689

    48,630

    Current portion of revenue interest liability, net

    865

    —

    Total current liabilities

    98,053

    88,015

    Long-term liabilities

    Operating lease liabilities, less current portion

    79,148

    89,388

    Deferred revenue, less current portion

    27,256

    44,793

    Revenue interest liability, net, less current portion

    132,414

    130,660

    Other long-term liabilities

    20

    —

    Total liabilities

    336,891

    352,856

    Commitments and contingencies (Note 12)

    Shareholders’ equity

    Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023

    —

    —

    Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2024 and 2023; 147,773,744 and 145,082,271 shares issued and outstanding at December 31, 2024 and 2023, respectively

    14

    14

    Additional paid-in capital

    1,506,353

    1,452,502

    Accumulated other comprehensive gain

    166

    215

    Accumulated deficit

    (1,303,824
    )

    (1,144,332
    )

    Total Adaptive Biotechnologies Corporation shareholders’ equity

    202,709

    308,399

    Noncontrolling interest

    (224
    )

    (121
    )

    Total shareholders’ equity

    202,485

    308,278

    Total liabilities and shareholders’ equity
     
    $
    539,376

    $
    661,134

The accompanying notes are an integral part of these consolidated financial statements.

91

Adaptive Biotechnologies Corporation

Consolidated Statements of Operations

(in thousands, except share and per